Medical Center Zara-Med EOOD
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Medical Center Zara-Med EOOD, investigators are exploring new therapies for heart failure, hypertension and high‑risk lipid disorders, aiming to improve survival and quality of life for patients with established cardiovascular disease.
- Novel lipid‑lowering agents targeting LDL‑C and triglycerides
- Studies on heart failure with preserved and reduced ejection fraction
- Combination therapy with empagliflozin for high‑risk cardiovascular patients
- Innovative antihypertensive approaches for uncontrolled hypertension
The site conducts 20 active trials with a team of 9 investigators, contributing valuable data to European cardiovascular research networks.
Musculoskeletal and Joint Disease Studies
Research at this facility includes advanced investigations into psoriatic arthritis, focusing on both biologic and small‑molecule treatments to achieve better joint function and reduce inflammation.
- Biologic agents such as sonelokimab evaluated for ACR50 response
- Small‑molecule inhibitor zasocitinib in patients naïve to biologic DMARDs
- Comparative studies with reference therapies like risankizumab
- Long‑term safety and tolerability monitoring
These trials support the development of targeted therapies for patients suffering from chronic joint disease in the Balkans region.
Metabolic and Nutritional Disorder Trials
The center is actively testing innovative treatments for metabolic conditions such as type 2 diabetes, hypertriglyceridemia and severe hypercholesterolemia, with the goal of reducing cardiovascular risk and improving metabolic control.
- RNA‑based therapies like plozasiran for triglyceride reduction
- Inclisiran to achieve aggressive LDL‑C targets
- Vicadrostat combined with empagliflozin for diabetic patients with hypertension
- Long‑term safety assessments of novel metabolic agents
By enrolling patients with high cardiovascular risk, the site contributes to the evidence base for next‑generation metabolic medicines.
Skin and Connective Tissue Condition Research
Investigations into chronic spontaneous urticaria aim to identify effective biologic options that can quickly relieve itching and wheals, enhancing patients’ daily functioning.
- Evaluation of anti‑IgE monoclonal antibody barzolvolimab
- Weekly urticaria activity score (UAS7) as primary efficacy endpoint
- Safety and tolerability profiling over a 12‑week period
- Assessment of quality‑of‑life improvements
The trial portfolio reflects a commitment to addressing unmet needs in dermatological care within the region.
Mental Health and Psychiatric Trials
The hospital conducts studies on major depressive disorder with prominent insomnia symptoms, testing adjunctive agents that may accelerate symptom relief and prevent relapse when combined with standard antidepressants.
- Adjunctive seltorexant added to SSRI/SNRI therapy
- Measurement of depressive symptom improvement and relapse delay
- Evaluation of sleep‑related outcomes alongside mood changes
- Monitoring of short‑ and long‑term safety in a psychiatric population
These efforts support the development of more comprehensive treatment strategies for patients struggling with mood disorders in Bulgaria.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Zara-Med EOOD
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 46 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.